
|Articles|January 10, 2007
Sutent and Nexavar Put Brakes on Renal-Cell Carcinoma
NEW YORK -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.
Advertisement
NEW YORK, Jan. 10 -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.
Sutent more than doubled progression-free survival (P
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
This Year in Primary Care: 10 Critical Updates in 2025
2
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
3
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
4
FDA Approves Abbott Volt Pulsed Field Ablation System for Treatment of Atrial Fibrillation
5




























































































































































































































































































